Linezolid Krka

Linezolid, the active ingredient in Linezolid Krka, is a oxazolidinone presented as an injection for intravenous use. It treats serious Gram‑positive bacterial infections, including methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE), in hospitalized patients.

GNH USA supplies Linezolid Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibacterial used to manage serious Gram‑positive infections, particularly those resistant to other agents. - Gram‑positive bacterial infections: provides bacteriostatic activity against a broad range of susceptible organisms, reducing disease severity. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers an effective alternative when beta‑lactams are ineffective. - Vancomycin‑resistant Enterococcus (VRE) infections: targets resistant enterococci, helping to control difficult‑to‑treat infections.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient gastrointestinal discomfort experienced by many patients. - Diarrhea: loose stools that may occur during therapy. - Headache: mild to moderate cranial pain reported in some cases. - Thrombocytopenia: reduction in platelet count, usually reversible after discontinuation. - Rash: skin erythema or mild dermatitis. - Vomiting: occasional emesis during treatment.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents. - Severe myelosuppression: profound bone‑marrow suppression leading to anemia or neutropenia. - Lactic acidosis: rare metabolic disturbance requiring immediate medical attention. - Optic neuropathy: vision changes that may be irreversible if not identified early.

Before initiating Linezolid therapy, clinicians should evaluate patient‑specific risk factors and monitor for complications. - Renal impairment: adjust monitoring as accumulation may occur. - Hepatic impairment: assess liver function because metabolism may be affected. - Hematologic monitoring: perform regular complete blood counts to detect thrombocytopenia or anemia. - Serotonergic agents: avoid concomitant use with SSRIs, SNRIs, or MAO inhibitors due to risk of serotonin syndrome. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - SSRIs, SNRIs, or other serotonergic antidepressants: risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis. - Tricyclic antidepressants: increase serotonin‑related toxicity. - Sympathomimetic agents (e.g., pseudoephedrine): can exacerbate hypertension.

Moderate Interactions (Monitor Closely): - Rifampin: induces hepatic enzymes, reducing linezolid plasma concentrations. - Warfarin: may enhance anticoagulant effect; monitor INR regularly. - Phenytoin: enzyme induction may lower linezolid levels, requiring efficacy assessment.